TY - JOUR
T1 - Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy
T2 - a pooled analysis
AU - Zhu, Jun
AU - Yeoh, Ee Min
AU - Maeda, Yoshinobu
AU - Tobinai, Kensei
N1 - Funding Information:
JZ: Nothing to disclose. EMY: Employee of Mundipharma. YM: Has received grants and honoraria from Takeda and Kyowa Hakko Kirin Co; and has also received honoraria from Chugai, Novartis, Otsuka, Astellas, AsahiKASEI, Sumitomo Dainippon, Mochida, Bristol-Myers Squibb, Pfizer, Nippon Shinyaku, Janssen, Celgene, Eisai, Mundipharma, and Meiji Seika. KT: Has received grants and personal fees from Mundipharma, Eisai, Takeda, Kyowa Hakko Kirin, Celgene, Chugai Pharma, and Ono Pharmaceutical; has also received personal fees from Zenyaku Kogyo, HUYA Bioscience International, Yakult, Daiichi Sankyo, Bristol-Myers Squibb, Meiji Seika Kaisha, Solasia Pharma, and Verastem; and has received grant support from Abbvie and Janssen.
Funding Information:
This study was funded by Mundipharma. The authors would like to thank Tomoko Murase and Rieko Ichihara, of Mundipharma Japan for their assistance in statistical support for this manuscript. Medical writing support was provided by Phillips Gilmore Oncology Communications and CoCre8ed Consulting.
Publisher Copyright:
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020/7/28
Y1 - 2020/7/28
N2 - Angioimmunoblastic T-cell lymphoma (AITL) is a histological subtype of peripheral T-cell lymphoma associated with a poor prognosis. This post-hoc pooled analysis aims to provide insight about the efficacy of pralatrexate monotherapy in a subset of twenty-nine patients with relapsed or refractory (r/r) AITL drawn from two prospective registration trials completed in China and Japan. After a median of two prior lines of therapy, an overall response rate of 52% (15/29 patients; 95% CI 0.34, 0.70) was demonstrated. The estimated median duration of response, progression free survival (PFS) and overall survival (OS) were 6.4 months (196 days), 5.0 months (151 days), and 18.0 months (548 days), respectively. Grades 1–3 mucositis was observed in twenty-three patients (79.3%); and hemato-toxicity in twenty-six (89.7%) patients. Results of this analysis corroborate with data from two previously reported US retrospective cohorts, supporting the potential benefits of pralatrexate monotherapy in patients with r/r AITL.
AB - Angioimmunoblastic T-cell lymphoma (AITL) is a histological subtype of peripheral T-cell lymphoma associated with a poor prognosis. This post-hoc pooled analysis aims to provide insight about the efficacy of pralatrexate monotherapy in a subset of twenty-nine patients with relapsed or refractory (r/r) AITL drawn from two prospective registration trials completed in China and Japan. After a median of two prior lines of therapy, an overall response rate of 52% (15/29 patients; 95% CI 0.34, 0.70) was demonstrated. The estimated median duration of response, progression free survival (PFS) and overall survival (OS) were 6.4 months (196 days), 5.0 months (151 days), and 18.0 months (548 days), respectively. Grades 1–3 mucositis was observed in twenty-three patients (79.3%); and hemato-toxicity in twenty-six (89.7%) patients. Results of this analysis corroborate with data from two previously reported US retrospective cohorts, supporting the potential benefits of pralatrexate monotherapy in patients with r/r AITL.
KW - AITL
KW - Angioimmunoblastic T-cell lymphoma
KW - PTCL
KW - peripheral T-cell lymphoma
KW - pralatrexate
KW - relapsed/refractory
UR - http://www.scopus.com/inward/record.url?scp=85087134207&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087134207&partnerID=8YFLogxK
U2 - 10.1080/10428194.2020.1765232
DO - 10.1080/10428194.2020.1765232
M3 - Article
C2 - 32536233
AN - SCOPUS:85087134207
VL - 61
SP - 2145
EP - 2152
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 9
ER -
